NLS Pharmaceutics Announces Promising Preclinical Data for Dual Orexin Receptor Agonists for Narcolepsy and Neurological Disorders
Dual-Action Drug Shows Promise in Preclinical trials for Narcolepsy Treatment
Zurich, Switzerland – NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) announced promising preclinical data for its innovative dual orexin receptor agonist (DOXA) platform, potentially revolutionizing narcolepsy treatment. The company’s lead candidates, AEX-41 and AEX-2, are designed to target both orexin-1 (OX1R) and orexin-2 (OX2R) receptors while simultaneously inhibiting cathepsins, enzymes implicated in various physiological processes.
Targeting Multiple Pathways for Enhanced Efficacy
The preclinical study, conducted at the Center for Neuroscience Research of Lyon, a leading European neuroscience research center, yielded encouraging results. In orexin knockout mice, AEX-41 demonstrated a important increase in wakefulness and a reduction in REM sleep duration, addressing core narcolepsy symptoms. Notably, its efficacy was comparable to sulfonamide-derivative selective OX2R agonists, highlighting its potential as a versatile alternative.
“The dual mechanism of AEX-41 marks a transformative approach in treating narcolepsy,” said dr.Eric Konofal, Chief Scientific Officer of NLS and inventor of the DOXA platform. “By simultaneously targeting orexin receptors and cathepsins,we aim to provide both symptomatic relief and disease-modifying potential – an advancement over current therapies.”
Expanding Research Horizons
building on these promising findings, NLS plans to expand its research in 2025, investigating the impact of AEX-41 on cathepsin H (CTSH) in animal models of neuroinflammation. This research could unlock new therapeutic avenues for neurodegenerative diseases, where neuroinflammation plays a crucial role.
an Investigational New Drug (IND) request is anticipated between 2026 and 2027 to support further clinical development of this novel approach.
Beyond Narcolepsy: A Broader Impact
NLS is actively advancing the development of both AEX-41 and AEX-2,with plans for further safety and efficacy evaluations in clinical settings. Beyond narcolepsy, the company is exploring their potential application in other neurodegenerative disorders, including amyotrophic lateral sclerosis (ALS), leveraging their unique dual-targeting mechanism.
Understanding Narcolepsy
Narcolepsy is a chronic sleep disorder characterized by excessive daytime sleepiness, cataplexy (sudden loss of muscle tone), and disrupted sleep patterns. It is indeed caused by the autoimmune destruction of orexin-producing neurons in the brain, leading to a deficiency of orexin, a neurotransmitter crucial for regulating wakefulness.
About NLS Pharmaceutics Ltd.
NLS Pharmaceutics is a global biopharmaceutical company dedicated to developing innovative therapies for rare and complex central nervous system disorders. With a robust pipeline targeting narcolepsy, idiopathic hypersomnia, and neurodegenerative diseases, NLS is committed to addressing unmet medical needs and improving the lives of patients worldwide.
NLS Pharmaceutics Reports Promising Preclinical Data for Novel Narcolepsy Treatment
New York, NY - NLS Pharmaceutics AG, a biopharmaceutical company focused on developing innovative treatments for central nervous system disorders, announced promising preclinical data for its first-in-class, non-sulfonamide dual orexin receptor agonists. These compounds show potential for treating narcolepsy and other neurological disorders.
the preclinical studies demonstrated the efficacy and safety profile of NLS’ lead candidates, AEX-41 and AEX-2. These novel compounds target the orexin system, which plays a crucial role in regulating wakefulness, sleep, and appetite.
“These results are a significant step forward in our mission to develop effective and safe treatments for patients suffering from narcolepsy and other debilitating neurological conditions,” said [Insert Name and Title of NLS Pharmaceutics Representative]. “Our dual orexin receptor agonists offer a unique approach by targeting both orexin receptors, potentially leading to improved efficacy and a broader therapeutic window compared to existing treatments.”
Narcolepsy is a chronic neurological disorder characterized by excessive daytime sleepiness, sudden sleep attacks, and other sleep-related disturbances. Current treatment options often come with side effects and may not fully address the complex symptoms of the disease.NLS Pharmaceutics is committed to advancing these promising candidates through further preclinical and clinical development. The company plans to submit an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) in the near future.
This breakthrough could offer hope to millions of Americans living with narcolepsy and other neurological disorders.
Dual-Action Drug Shows Promise in Preclinical Trials for Narcolepsy
zurich, Switzerland – Could a revolutionary new drug be on the horizon for narcolepsy sufferers?
New data from pre-clinical trials conducted by NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) suggest that thier led candidates, AEX-41 and AEX-2, may hold the key too more effective treatment.
These drugs are unique due to their dual-action mechanism. They act as dual orexin receptor agonists (DOXA), meaning they target both orexin-1 (OX1R) and orexin-2 (OX2R) receptors. This is significant as orexin neurons play a pivotal role in regulating wakefulness and sleep cycles. Deficiencies in these neurons are a hallmark of narcolepsy.
Adding to their potential is the fact that these drugs also inhibit cathepsins, enzymes involved in various physiological processes.
To discuss the implications of these findings, we spoke with Dr.[[[[Insert Name HERE], a leading specialist in[[[[Insert Relevant Specialty HERE].
NewsDirector3: Dr.[[[[name], these findings seem incredibly promising. How significant are these results for the field of narcolepsy treatment?
Dr. [Name]: the potential of these dual-action drugs is truly exciting.Current treatments for narcolepsy, while helpful, often only address some symptoms and can have significant side effects. AEX-41 and AEX-2 offer a new approach targeting multiple pathways involved in the disease, which could lead to more extensive and effective treatment.
NewsDirector3: The preclinical trial showed marked betterment in wakefulness and reduction in REM sleep duration in orexin knockout mice. Could you elaborate on the significance of these findings?
Dr. [Name]: These findings directly address core symptoms of narcolepsy. the increased wakefulness indicates the drugs’ ability to combat excessive daytime sleepiness, a major challenge for narcolepsy patients. The reduction in REM sleep duration is also crucial as it helps normalize sleep patterns and potentially reduce cataplexy,a sudden loss of muscle tone triggered by strong emotions.
NewsDirector3: One intriguing aspect is the comparison to sulfonamide-derivative selective OX2R agonists. What does this tell us about the potential versatility of AEX-41?
Dr. [Name]: The fact that AEX-41 showed comparable efficacy to these selective agonists while also targeting OX1R receptors is highly encouraging. It suggests that this dual-action approach could offer a more tailored treatment with potentially fewer side effects.
NewsDirector3: What are the next steps for bringing these drugs to market?
Dr. [Name]: The promising preclinical data are just the first step.
NLS Pharmaceutics will now move forward with clinical trials in humans to assess the safety and efficacy of AEX-41 and AEX-2 in narcolepsy patients. These trials will be critical in determining the drug’s potential to transform narcolepsy treatment.
NewsDirector3: Dr.[[[[Name], thank you for sharing your insights on this groundbreaking research.
[End Interview]
Note: this interview segment assumes you will insert the name of an appropriate specialist. The information provided needs to be tailored to the chosen specialist’s expertise for a natural and informative interview. Additionally, you can expand on specific aspects of the findings or the drug’s mechanism of action depending on the chosen specialist’s area of focus.